Cirrus Logic Reports Strong Q3 Earnings, Shares Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy AMGN?
Source: Benzinga
- Earnings Beat: Cirrus Logic reported third-quarter earnings of $2.97 per share, surpassing the analyst consensus estimate of $2.44 per share, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $580.620 million, exceeding the analyst consensus estimate of $533.890 million, demonstrating strong market demand and driving sustained performance growth.
- Stock Surge: Following the positive earnings report, Cirrus Logic's shares jumped 7.6% to $134.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Optimistic Guidance: Cirrus Logic provided fourth-quarter sales guidance that is expected to exceed market estimates, further solidifying its competitive position in the semiconductor industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 345.87 USD with a low forecast of 272.00 USD and a high forecast of 425.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
11 Buy
7 Hold
1 Sell
Moderate Buy
Current: 338.590
Low
272.00
Averages
345.87
High
425.00
Current: 338.590
Low
272.00
Averages
345.87
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amgen Showcases MariTide Potential at J.P. Morgan Conference
- MariTide Progress: At the 44th Annual J.P. Morgan Healthcare Conference, Amgen showcased the latest developments of MariTide, which is expected to attract significant investor attention due to its potential in obesity and type 2 diabetes treatment, potentially driving future revenue growth for the company.
- Market Outlook: With rising global obesity rates, the successful development of MariTide could not only improve patient health but also open new market opportunities for Amgen, thereby enhancing its competitiveness in the biopharmaceutical industry.
- Investor Focus: Amgen's Q4 preview indicates that investors will closely monitor MariTide's progress, especially during the upcoming earnings release, where successful clinical trial results could significantly boost the company's stock price.
- Industry Impact: Amgen's performance at the conference may influence investment trends across the biopharmaceutical sector, particularly in the obesity and metabolic disease fields, further driving R&D investments and market competition among related companies.
See More
Bitcoin-Related Stocks Plummet Amid Decline
- Bitcoin Market Volatility: Bitcoin dropped over 3% during midday trading, causing related stocks like Strategy to fall more than 8%, reflecting a decline in market confidence in cryptocurrencies, which may affect investors' risk appetite.
- MGM Resorts Profit Growth: MGM Resorts announced that its joint venture BetMGM reached profitability, with net revenue of $2.8 billion in 2025, up 33%, indicating success in the sports betting sector that could drive its stock price higher.
- Strong Biotechnology Performance: Amgen's stock rose 8% following its fourth-quarter earnings report, with adjusted earnings of $5.29 per share exceeding analyst expectations of $4.73, showcasing its competitiveness and market confidence in the biotech field.
- Software Sector Decline: Palantir's shares fell 13% as investors took profits after its earnings report, while the broader software sector faced pressure due to concerns over artificial intelligence, indicating a cautious market sentiment towards tech stocks.
See More
Market Volatility and Stock Performance Recap
- Tech Stock Pressure: Despite attempts by high-multiple tech stocks like Microsoft to bounce back, the broader market remains under pressure due to fears that AI disruption could undermine traditional enterprise software companies, with the S&P 500 and Nasdaq down 1% and 2%, respectively.
- Eli Lilly Strong Performance: Pharmaceutical giant Eli Lilly saw its shares rise nearly 10% after delivering a significant earnings beat, indicating strong market confidence in its future growth and likely enhancing its market share in the pharmaceutical sector.
- Eaton Stock Volatility: Eaton's stock fluctuated near the flat line after a mixed fourth-quarter report, ultimately closing up nearly 1%, with investor focus on the planned spinoff of its mobility business in 2027 potentially serving as a future catalyst for growth.
- GE Vernova Decline: Despite an upgrade from Baird to outperform, GE Vernova's shares fell 7.5% to around $722, reflecting market concerns about the energy infrastructure cycle, although analysts expressed optimism about avoiding overcapacity issues in the near term.
See More
Cirrus Logic Reports Strong Q3 Earnings, Shares Surge
- Earnings Beat: Cirrus Logic reported third-quarter earnings of $2.97 per share, surpassing the analyst consensus estimate of $2.44 per share, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $580.620 million, exceeding the analyst consensus estimate of $533.890 million, demonstrating strong market demand and driving sustained performance growth.
- Stock Surge: Following the positive earnings report, Cirrus Logic's shares jumped 7.6% to $134.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Optimistic Guidance: Cirrus Logic provided fourth-quarter sales guidance that is expected to exceed market estimates, further solidifying its competitive position in the semiconductor industry.
See More
Amgen Reports Strong Q4 Earnings Exceeding Expectations
- Significant Revenue Growth: Amgen's Q4 revenues increased by 9% to $9.9 billion, with product sales up 7%, despite a 4% decline in net selling price, indicating strong performance from key drivers like Repatha and Uplizna, suggesting future growth potential.
- Annual Performance Improvement: For the full year 2022, revenues rose by 10% to $36.8 billion, with product sales also up 10%, and 13 products achieving double-digit growth, demonstrating the company's competitive strength and sustained demand in the market.
- Optimistic Future Outlook: Amgen forecasts total revenues between $37 billion and $38.4 billion for 2026, with earnings per share expected in the range of $15.45 to $16.94, reflecting confidence in future growth, particularly from the upside potential of recent label updates.
- Analyst Rating Adjustment: Analyst Carter Gould from Cantor Fitzgerald reiterated a Neutral rating while raising the price target from $315 to $350, reflecting an optimistic outlook on Amgen's future performance.
See More
Movers in the Market: AMD, Super Micro, Enphase, Alphabet, Chipotle, Silicon Labs, Novo Nordisk, and Others
- Stock Market Trends: Stock futures showed a mostly higher trend on Wednesday after a recent selloff.
- Concerns Over AI Impact: The selloff was driven by concerns regarding the implications of the artificial intelligence boom for software companies.
See More
Amgen Showcases MariTide Potential at J.P. Morgan Conference
- MariTide Progress: At the 44th Annual J.P. Morgan Healthcare Conference, Amgen showcased the latest developments of MariTide, which is expected to attract significant investor attention due to its potential in obesity and type 2 diabetes treatment, potentially driving future revenue growth for the company.
- Market Outlook: With rising global obesity rates, the successful development of MariTide could not only improve patient health but also open new market opportunities for Amgen, thereby enhancing its competitiveness in the biopharmaceutical industry.
- Investor Focus: Amgen's Q4 preview indicates that investors will closely monitor MariTide's progress, especially during the upcoming earnings release, where successful clinical trial results could significantly boost the company's stock price.
- Industry Impact: Amgen's performance at the conference may influence investment trends across the biopharmaceutical sector, particularly in the obesity and metabolic disease fields, further driving R&D investments and market competition among related companies.
See More
Bitcoin-Related Stocks Plummet Amid Decline
- Bitcoin Market Volatility: Bitcoin dropped over 3% during midday trading, causing related stocks like Strategy to fall more than 8%, reflecting a decline in market confidence in cryptocurrencies, which may affect investors' risk appetite.
- MGM Resorts Profit Growth: MGM Resorts announced that its joint venture BetMGM reached profitability, with net revenue of $2.8 billion in 2025, up 33%, indicating success in the sports betting sector that could drive its stock price higher.
- Strong Biotechnology Performance: Amgen's stock rose 8% following its fourth-quarter earnings report, with adjusted earnings of $5.29 per share exceeding analyst expectations of $4.73, showcasing its competitiveness and market confidence in the biotech field.
- Software Sector Decline: Palantir's shares fell 13% as investors took profits after its earnings report, while the broader software sector faced pressure due to concerns over artificial intelligence, indicating a cautious market sentiment towards tech stocks.
See More
Market Volatility and Stock Performance Recap
- Tech Stock Pressure: Despite attempts by high-multiple tech stocks like Microsoft to bounce back, the broader market remains under pressure due to fears that AI disruption could undermine traditional enterprise software companies, with the S&P 500 and Nasdaq down 1% and 2%, respectively.
- Eli Lilly Strong Performance: Pharmaceutical giant Eli Lilly saw its shares rise nearly 10% after delivering a significant earnings beat, indicating strong market confidence in its future growth and likely enhancing its market share in the pharmaceutical sector.
- Eaton Stock Volatility: Eaton's stock fluctuated near the flat line after a mixed fourth-quarter report, ultimately closing up nearly 1%, with investor focus on the planned spinoff of its mobility business in 2027 potentially serving as a future catalyst for growth.
- GE Vernova Decline: Despite an upgrade from Baird to outperform, GE Vernova's shares fell 7.5% to around $722, reflecting market concerns about the energy infrastructure cycle, although analysts expressed optimism about avoiding overcapacity issues in the near term.
See More
Cirrus Logic Reports Strong Q3 Earnings, Shares Surge
- Earnings Beat: Cirrus Logic reported third-quarter earnings of $2.97 per share, surpassing the analyst consensus estimate of $2.44 per share, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $580.620 million, exceeding the analyst consensus estimate of $533.890 million, demonstrating strong market demand and driving sustained performance growth.
- Stock Surge: Following the positive earnings report, Cirrus Logic's shares jumped 7.6% to $134.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Optimistic Guidance: Cirrus Logic provided fourth-quarter sales guidance that is expected to exceed market estimates, further solidifying its competitive position in the semiconductor industry.
See More
Amgen Reports Strong Q4 Earnings Exceeding Expectations
- Significant Revenue Growth: Amgen's Q4 revenues increased by 9% to $9.9 billion, with product sales up 7%, despite a 4% decline in net selling price, indicating strong performance from key drivers like Repatha and Uplizna, suggesting future growth potential.
- Annual Performance Improvement: For the full year 2022, revenues rose by 10% to $36.8 billion, with product sales also up 10%, and 13 products achieving double-digit growth, demonstrating the company's competitive strength and sustained demand in the market.
- Optimistic Future Outlook: Amgen forecasts total revenues between $37 billion and $38.4 billion for 2026, with earnings per share expected in the range of $15.45 to $16.94, reflecting confidence in future growth, particularly from the upside potential of recent label updates.
- Analyst Rating Adjustment: Analyst Carter Gould from Cantor Fitzgerald reiterated a Neutral rating while raising the price target from $315 to $350, reflecting an optimistic outlook on Amgen's future performance.
See More
Movers in the Market: AMD, Super Micro, Enphase, Alphabet, Chipotle, Silicon Labs, Novo Nordisk, and Others
- Stock Market Trends: Stock futures showed a mostly higher trend on Wednesday after a recent selloff.
- Concerns Over AI Impact: The selloff was driven by concerns regarding the implications of the artificial intelligence boom for software companies.
See More
